-

07:13:01 PM

APVO Stock News

APVO - Aptevo Therapeutics Inc

11/23/21 8:05 AM

Nasdaq : APVO

clinical triallow float

Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today

RHEA-AI

positive

11/15/21 8:05 AM

Nasdaq : APVO

conferenceslow float

Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today

RHEA-AI

neutral

11/12/21 8:05 AM

Nasdaq : APVO

earningslow float

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today

RHEA-AI

neutral

11/11/21 4:45 PM

Nasdaq : APVO

low float

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Alligator Bioscience AB (" Alligator") and Aptevo Therapeutics ("Aptevo") today announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor

RHEA-AI

neutral

11/11/21 8:30 AM

Nasdaq : APVO

clinical triallow float

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel

RHEA-AI

neutral

10/27/21 8:05 AM

Nasdaq : APVO

clinical triallow float

Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, will

RHEA-AI

neutral

10/26/21 8:05 AM

Nasdaq : APVO

low float

Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436

Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today

RHEA-AI

negative

09/28/21 8:05 AM

Nasdaq : APVO

low float

Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-risk adult

RHEA-AI

neutral

08/17/21 8:05 AM

Nasdaq : APVO

low float

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

RHEA-AI

neutral

08/12/21 8:05 AM

Nasdaq : APVO

earningslow float

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported

RHEA-AI

neutral

APVO Data:

IndustryPharmaceutical Preparation Manufacturing
Websiteaptevotherapeutics.com
Security nameAptevo Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees58
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2401 4th Ave Ste 1050
StateWashington
CitySeattle
Zip98121-3460
CountryUS
Phone12068380500

APVO Description:

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.